Medtronic plc (MDT)
Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
Medtronic's fair price estimate is $142.20, indicating a 73.3% upside from $82.07, with potential annual returns of 28.8% through 2029. FQ4 2024 earnings exceeded expectations with an EPS of $1.46 and revenue of $8.59 billion. Medtronic focuses on innovation through AI, data analytics, and new partnerships, enhancing competitiveness and product offerings.
Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?
Medtronic stock reacted negatively to an earnings report that many Wall Street analysts found encouraging. Wells Fargo raised its price target for Medtronic to $105 per share.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic Dips: Is Now the Time to Buy?
Shares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow are enough to keep investors interested and if they should be.
Medtronic's Mixed Q4 Earnings Report
Medtronic's top line saw growth in Q4 and full-year, but that growth disappeared in the bottom-line figures. Medtronic management was positive in its outlook for fiscal 25 with projected organic revenue growth of 4%-5%.
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Medtronic plc (MDT) Q4 2024 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q4 2024 Earnings Conference Call May 23, 2024 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Executive Vice President and Chief Financial Officer Brad Welnick - Vice President, Investor Relations Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Brett Wall - Executive Vice President and President, Neuroscience Portfolio Mike Marinaro - Executive Vice President and President, Medical Surgical Portfolio and Surgical Operating Unit Que Dallara - Executive Vice President and President, Diabetes Operating Unit Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Vijay Kumar - Evercore ISI Lawrence Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Joshua Jennings - Cowen and Company Richard Newitter - Truist Securities Matt Miksic - Barclays Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and I appreciate that you're joining us this morning for our Fiscal '24 Fourth Quarter Video Earnings Webcast.
Why Medtronic Stock Slumped Today
Medtronic beat on sales and earnings and gave exactly the guidance that Wall Street expected. Its stock dropped today anyway.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic Q4 earnings: ‘we're optimistic about fiscal 2025'
Medtronic PLC (NYSE: MDT) is in focus on Thursday after reporting market-beating financial results for its fourth quarter. Medtronic issues in-line guidance The stock is flat at writing because $MDT issued roughly in-line guidance for the full year.
Medtronic Q4 earnings: ‘we're optimistic about fiscal 2025'
Medtronic PLC (NYSE: MDT) is in focus on Thursday after reporting market-beating financial results for its fourth quarter. Medtronic issues in-line guidance The stock is flat at writing because $MDT issued roughly in-line guidance for the full year.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
Medtronic (MDT) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.57 per share a year ago.
